Management Of Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction: Viewpoints from the Medical Oncologist, Dermatologist, and Oncology Nurse

Journal of Supportive Oncology

Volumn 9, Issue 1, 2011, Pages 13-23

  Manchen, Elizabeth ^a   Robert, Caroline ^a   Porta, Camillo ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; IMATINIB; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TOPICAL AGENT;

ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRY SKIN; DYSESTHESIA; FACE ERYTHEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SKIN REACTION; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NURSING CARE; PATHOPHYSIOLOGY; PATIENT EDUCATION; PROTECTIVE CLOTHING; RASH; SCALP DYSESTHESIA; SKIN CARE; SKIN EXFOLIATION; SKIN TOXICITY; SOFT TISSUE SARCOMA; VOMITING;

BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; DERMATOLOGY; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INDOLES; MEDICAL ONCOLOGY; ONCOLOGIC NURSING; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES;

EID: 79955970528     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suponc.2010.12.007     Document Type: Article

References (49)

1. Porta C., Paglino C., Imarisio I., Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007, 7:127-134.
2. Lipworth A.D., Robert C., Zhu A.X. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009, 77:257-271. [19923864].
3. Lacouture M.E., Wu S., Robert C., et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008, 13:1001-1011. [18779536].
4. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7:3129-3140. [18852116].
5. Auclair D., Miller D., Yatsula V., et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007, 21:439-445. [17205056].
6. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006, 98:326-334. [16507829].
7. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109. [15466206].
8. Christensen J.G. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007, 10:x3-x10. [17761721].
9. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. [17215530].
10. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol 2009, 27:3312-3318. [19451442].
11. Stadler W.M., Figlin R.A., McDermott D.F., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280. [20082451].
12. Beck J., Bajetta E., Escudier B., et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer 2007, (suppl):5. Abstract 4506.
13. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. [18650514].
14. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34. [19095497].
15. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338. [17046465].
16. Demetri G.D., Huang X., Garrett C.R., et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol 2008, (suppl):26. Abstract 10524.
17. Reichardt P., Kang Y., Ruka W., et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol 2008, (suppl):26. Abstract 10548.
18. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124. [17215529].
19. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590. [19487381].
20. Gore M.E., Szczylik C., Porta C., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763. [19615940].
21. Blumenschein G.R., Gatzemeier U., Fossella F., et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:4274-4280. [19652055].
22. Schütte H.J., Schlemmer M., Wendtner C., Reichardt P., Demetri G.D. Sunitinib (SU) in a worldwide treatment-use trial of pts with advanced gastrointestinal stromal tumours (GIST): analysis of survival and safety data. Onkologie 2008, (suppl 4):201. Abstract V582.
23. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524. [16757724].
24. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512. [16636341].
25. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300. [16908937].
26. Hutson T.E., Davis I.D., Machiels J.P., et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010, 28:475-480. [20008644].
27. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068. [20100962].
28. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8:975-984. [17959415].
29. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99:81-83. [17202116].
30. Rini B.I., Wilding G., Hudes G., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4462-4468. [19652060].
31. Rugo H.S., Herbst R.S., Liu G., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005, 23:5474-5483. [16027439].
32. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.02. NIH publication 03-5410 2009, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services, National Institutes of Health, Bethesda, MD.
33. Wood L.S., Manchen B. Sorafenib: a promising new targeted therapy for renal cell carcinoma. Clin J Oncol Nurs 2007, 11:649-656. [17962173].
34. Robert C., Mateus C., Spatz A., Wechsler J., Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009, 60:299-305. [19028406].
35. Autier J., Escudier B., Wechsler J., Spatz A., Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008, 144:886-892. [18645140].
36. Lacouture M.E., Reilly L.M., Gerami P., Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008, 19:1955-1961. [18550575].
37. Wood L.S. Managing the side effects of sorafenib and sunitinib. Community Oncol 2006, 3:558-562.
38. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005, 6:491-500. [15992698].
39. Saif M.W., Merikas I., Tsimboukis S., Syrigos K. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 2008, 9:267-274. [18469438].
40. Anderson R., Jatoi A., Robert C., Wood L.S., Keating K.N., Lacouture M.E. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009, 14:291-302. [19276294].
41. Gawkrodger D.J. Dermatology: An Illustrated Colour Text, 4th ed 2008, Churchill Livingstone Elsevier, Edinburgh.
42. Azad N.S., Aragon-Ching J.B., Dahut W.L., et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009, 15:1411-1416. [19228742].
43. Bhojani N., Jeldres C., Patard J.J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008, 53:917-930. [18054825].
44. Sleijfer S., Ray-Coquard I., Papai Z., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009, 27:3126-3132. [19451427].
45. Wood L.S., Lemont H., Jatoi A., et al. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncol 2010, 7:23-29.
46. Esper P., Gale D., Muehlbauer P. What kind of rash is it?. Deciphering the dermatologic toxicities of biologic and targeted therapies. Clin J Oncol Nurs 2007, 11:659-666. [17962174].
47. Hagemann I., Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 1996, 76:353-356. [8891006].
48. Duvic M., Asano A.T., Hager C., Mays S. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 1998, 39:S129-S133. [9777790].
49. Scheithauer W., McKendrick J., Begbie S., et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003, 14:1735-1743. [14630678].